Orchard Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Orchard Therapeutics es Bobby Gaspar , nombrado en Mar 2020, tiene una permanencia de 3.83 años. compensación anual total es $1.45M, compuesta por 39.6% salario y 60.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.16% de las acciones de la empresa, por valor de $611.47K. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 5.6 años, respectivamente.
Información clave
Bobby Gaspar
Chief Executive Officer (CEO)
US$1.4m
Compensación total
| Porcentaje del salario del CEO | 39.6% |
| Permanencia del CEO | 3.8yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 2.7yrs |
| Promedio de permanencia en la Junta Directiva | 5.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$85m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$1m | US$573k | -US$151m |
| Sep 30 2022 | n/a | n/a | -US$179m |
| Jun 30 2022 | n/a | n/a | -US$168m |
| Mar 31 2022 | n/a | n/a | -US$154m |
| Dec 31 2021 | US$4m | US$605k | -US$145m |
| Sep 30 2021 | n/a | n/a | -US$142m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$137m |
| Dec 31 2020 | US$4m | US$543k | -US$152m |
| Sep 30 2020 | n/a | n/a | -US$164m |
| Jun 30 2020 | n/a | n/a | -US$180m |
| Mar 31 2020 | n/a | n/a | -US$183m |
| Dec 31 2019 | US$921k | US$344k | -US$163m |
| Sep 30 2019 | n/a | n/a | -US$143m |
| Jun 30 2019 | n/a | n/a | -US$140m |
| Mar 31 2019 | n/a | n/a | -US$246m |
| Dec 31 2018 | US$2m | US$338k | -US$230m |
Compensación vs. Mercado: La compensación total de Bobby($USD1.45M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.18M).
Compensación vs. Ingresos: La compensación de Bobby ha sido consistente con los resultados de la empresa en el último año.
CEO
Bobby Gaspar (60 yo)
3.8yrs
Permanencia
US$1,447,526
Compensación
Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Member of Scientific Advisory Board & Executive Director | 3.8yrs | US$1.45m | 0.16% $ 611.5k | |
| President & COO | 4yrs | US$1.21m | 0.040% $ 153.8k | |
| Chief Technical Officer | 2.3yrs | sin datos | sin datos | |
| Chief Scientific Officer | 2yrs | sin datos | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Director of Corporate Communications | no data | sin datos | sin datos | |
| Chief Human Resource Officer | no data | sin datos | sin datos | |
| Senior VP & GM of EMEA Commercial Operations | 5.2yrs | sin datos | sin datos | |
| Chief Commercial Officer | 3yrs | sin datos | sin datos | |
| Chief Medical Officer | 2.3yrs | sin datos | sin datos | |
| Company Secretary | 1.9yrs | sin datos | sin datos |
2.7yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de ORTX se considera experimentado (2.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Member of Scientific Advisory Board & Executive Director | 7.9yrs | US$1.45m | 0.16% $ 611.5k | |
| Independent Chairman | 5.7yrs | US$107.72k | 0.019% $ 74.1k | |
| Independent Non-Executive Director | 5.6yrs | US$71.72k | 0.016% $ 62.1k | |
| Independent Non-Executive Director | 5.5yrs | US$90.72k | 0.0054% $ 20.5k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
5.6yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de ORTX se considera experimentada (5.6 años de antigüedad promedio).